The Antiemetic Efficacy of Oral Ondansetron plus Intravenous Dexamethasone in Patients with Gynecologic Malignancies Receiving Carboplatin-Based Chemotherapy

Markman, Maurie; Kennedy, Alexander W.; Webster, Kenneth; Peterson, Gertrude; Kulp, Barbara; Belinson, Jerome L.

doi:10.1006/gyno.2000.5824

Cited by 6 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, it is noteworthy that while 8 mg of intravenous ondansetron is recommended by guidelines [3] and is commonly used in clinical practice, the prescribing information recommends a single high dose or multiple daily doses. Oral ondansetron, 16 mg, has been found to be effective when used with a corticosteroid in the treatment of emesis resulting from moderately emetogenic chemotherapy [42, 43] and for oral administration, 8 mg ondansetron twice daily is currently recommended by guidelines [3]. A once-daily 8-mg dose of oral ondansetron has also been investigated, but it failed to prevent nausea and vomiting following moderately emetogenic chemotherapy and as such, is not recommended [44].…”

Section: The Influence Of Different Chemotherapy Regimensmentioning

confidence: 99%

5-HT<sub>3</sub>-Receptor Antagonists in the Management of Nausea and Vomiting in Cancer and Cancer Treatment

Aapro¹

2005

Oncology

View full text Add to dashboard Cite

The 5-HT₃-receptor antagonists, considered as ‘gold standard’ therapy for cancer patients, are generally perceived to have similar efficacy and safety profiles, andmost antiemetic guidelines do not distinguish between agents. However, important pharmacological differences exist between agents, which may translate into potential benefits for some patients. In particular, 5-HT₃-receptor antagonists vary in the nature of their receptor antagonism and plasma half-lives, possibly leading to differences in duration of action. Agents with a longer duration of action provide antiemetic protection throughout the acute emetic period (24 h) with a single daily dose, whereas shorter-acting agents, e.g. ondansetron, may require multiple dosing for full efficacy. Differences also exist between agents in their hepatic metabolism and cardiovascular safety, which may present particular problems for elderly patients who often receive additional medications for comorbid conditions, increasing the risk of drug-drug interaction. Recent antiemetic guidelines from the National Comprehensive Cancer Network recommend preferential use of palonosetron for moderately emetogenic chemotherapy; however, this agent is newly approved and key clinical questions remain unanswered by clinical trial data. Selection of an appropriate 5-HT₃-receptor antagonist should be based on proven efficacy and safety, as well as on the individual characteristics of the patient.

show abstract

Section: The Influence Of Different Chemotherapy Regimensmentioning

confidence: 99%